Curemark, VTT Molecular Sciences Institute collaborate
Tuesday, August 27, 2013
Curemark, a drug R&D company focused on neurological disorders, has entered into a collaborative research agreement with the VTT Molecular Sciences Institute (MSI), an independent, nonprofit research institute in Berkeley, Calif.
“Tapping into MSI’s expertise will deepen our knowledge of the full nature of our proprietary enzyme’s biological properties,” said Dr. Matthew Heil, Curemark’s chief scientific officer. “We expect this research will lead to multiple additional indications and formulation possibilities, which will benefit people with unmet medical needs.”